If you enjoy this content, please share it with a colleague
RELATED CONTENT
August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...
September 2, 2015 — Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small ...
In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not, according to results of Delayed Enhancement — MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) trial.
September 11, 2012 — Data presented at the 2012 ESC Congress in Munich from the prospective DeFACTO study show that, when compared to standard coronary angiography, the noninvasive assessment of fractional flow reserve by computed tomography (FFR-CT) provides a more accurate determination of which lesions require invasive evaluation.
December 8, 2011 — Two new studies report that echocardiography has a central role to play in identifying patients at risk of suffering heart damage from cancer therapies. They also report the procedure can be used in evaluating potential cardio protective treatments. Both studies were presented at EUROECHO 2011, held Dec. 7-10 in Budapest, Hungary.
December 8, 2011 — Speckle training echocardiography (STE) is the subject of two studies being presented at EUROECHO 2011, Dec. 7-10 in Budapest, Hungary. They compare STE, a recent echocardiography technique, with magnetic resonance imaging (MRI) in quantifying infarct size (IS) after ST-elevation myocardial infarction (STEMI). MRI is the current gold standard for IS quantification.
November 7, 2011 — This year’s annual meeting of the European Association of Echocardiography (EAE), a registered branch of the European Society of Cardiology (ESC), is changing its name to “EUROECHO & other Imaging Modalities.”